Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis.

ABSTRACT:

Background

Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain.

Objective

This systematic review evaluated moderate-intensity statin plus ezetimibe dual therapy versus high-intensity statin monotherapy for NO-T2DM risk.

Methods

Five databases were searched to identify eligible studies. Random-effects meta-analyses generated pooled relative risks (RR) quantifying the effect of ezetimibe plus moderate-intensity statins on NO-T2DM. The Attributable Risk Fraction (ARF) was quantified utilizing the pooled estimate.

Results

Ten observational studies and four clinical trials were in

SUBMITTER: Albawa'neh AS 

PROVIDER: S-EPMC12671431 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature